WilfortrineCAS# 37239-48-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 37239-48-8 | SDF | Download SDF |
| PubChem ID | 73321 | Appearance | Powder |
| Formula | C41H47NO20 | M.Wt | 873.8 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC(=O)OCC12C(C(C3C(C14C(C(C(C2OC(=O)C)OC(=O)C5=COC=C5)OC(=O)C(CCC6=C(C=CC=N6)C(=O)OCC3(O4)C)(C)O)(C)O)OC(=O)C)OC(=O)C)OC(=O)C | ||
| Standard InChIKey | JOKOHWLSQAZHFX-FYBNDBPCSA-N | ||
| Standard InChI | InChI=1S/C41H47NO20/c1-19(43)54-18-40-32(58-22(4)46)28(56-20(2)44)27-30(57-21(3)45)41(40)39(8,52)31(29(33(40)59-23(5)47)60-34(48)24-12-15-53-16-24)61-36(50)37(6,51)13-11-26-25(10-9-14-42-26)35(49)55-17-38(27,7)62-41/h9-10,12,14-16,27-33,51-52H,11,13,17-18H2,1-8H3/t27-,28-,29+,30-,31+,32-,33+,37?,38+,39?,40-,41+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Wilfortrine can induce liver cancer cell HepG2 apoptosis, but with no effect on the cell cycle, mainly by promoting Bax expression and inhibiting anti-apoptotic protein Bcl-2 expression. The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug. Wilfortrine and euonine (40.80 mg/(kg.d) x 4d ip) show marked depressant effects on humoral mediated immunity using the hemolysin reaction as indices. |
| Targets | Bcl-2/Bax | Immunology & Inflammation related |
| In vitro | Effect of wilfortrine on human hepatic cancer HepG2 cell proliferation potential in vitro.[Pubmed: 26634500 ]Genet Mol Res. 2015 Nov 30;14(4):15349-55.Liver cancers are characterized by high morbidity and mortality owing to few effective drugs for its treatment. Wilfortrine has several pharmacological effects, including an inhibitory effect on liver cancer cell proliferation. However, whether Wilfortrine can induce liver cancer cell apoptosis has not been elucidated. |
| In vivo | Immunosuppresive effects of wilfortrine and euonine.[Pubmed: 2618700]Yao Xue Xue Bao. 1989;24(8):568-72.Wifortrine and Euonine isolated from Tripterygium wilfordii Hook. f. |
| Kinase Assay | Effect of Combined Treatment Using Wilfortrine and Paclitaxel in Liver Cancer and Related Mechanism.[Pubmed: 27043783 ]Med Sci Monit. 2016 Apr 4;22:1109-14.Liver cancer is a common malignant tumor with high mortality. Currently, effective medicines against liver cancer are still lacking. Paclitaxel is a wide-spectrum anti-tumor agent, while Wilfortrine has been shown to have an inhibitory effect on the proliferation of liver cancer cells. This study thus investigated the potential effect of paclitaxel combined with Wilfortrine on cultured liver cancer cells and related mechanisms, in order to provide evidence for pathogenesis and treatment of liver cancer.
|
Wilfortrine Dilution Calculator
Wilfortrine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1444 mL | 5.7221 mL | 11.4443 mL | 22.8885 mL | 28.6107 mL |
| 5 mM | 0.2289 mL | 1.1444 mL | 2.2889 mL | 4.5777 mL | 5.7221 mL |
| 10 mM | 0.1144 mL | 0.5722 mL | 1.1444 mL | 2.2889 mL | 2.8611 mL |
| 50 mM | 0.0229 mL | 0.1144 mL | 0.2289 mL | 0.4578 mL | 0.5722 mL |
| 100 mM | 0.0114 mL | 0.0572 mL | 0.1144 mL | 0.2289 mL | 0.2861 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Wilforgine
Catalog No.:BCN5427
CAS No.:37239-47-7
- Sieber Linker
Catalog No.:BCC2835
CAS No.:3722-51-8
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- Citromycin
Catalog No.:BCN7459
CAS No.:37209-30-6
- Capsidiol
Catalog No.:BCC8140
CAS No.:37208-05-2
- L-Citruline
Catalog No.:BCN2692
CAS No.:372-75-8
- SB 612111 hydrochloride
Catalog No.:BCC7714
CAS No.:371980-94-8
- ZAPA sulfate
Catalog No.:BCC6563
CAS No.:371962-01-5
- YM201636
Catalog No.:BCC4996
CAS No.:371942-69-7
- PI-103 Hydrochloride
Catalog No.:BCC1860
CAS No.:371935-79-4
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- Flavoxate hydrochloride
Catalog No.:BCC5208
CAS No.:3717-88-2
- Wilfordine
Catalog No.:BCN3083
CAS No.:37239-51-3
- TCS OX2 29
Catalog No.:BCC7670
CAS No.:372523-75-6
- Sennoside C
Catalog No.:BCN1004
CAS No.:37271-16-2
- Sennoside D
Catalog No.:BCN1005
CAS No.:37271-17-3
- H-D-Tyr-OMe.HCl
Catalog No.:BCC3135
CAS No.:3728-20-9
- Flavokawain C
Catalog No.:BCN8456
CAS No.:37308-75-1
- 3-Quinuclidinone
Catalog No.:BCC8642
CAS No.:3731-38-2
- Decloxizine
Catalog No.:BCC5529
CAS No.:3733-63-9
- Cephaeline Hydrochloride
Catalog No.:BCC8307
CAS No.:3738-70-3
- DS2
Catalog No.:BCC7748
CAS No.:374084-31-8
- Boc-DL-Ala-OH
Catalog No.:BCC3050
CAS No.:3744-87-4
- Istaroxime hydrochloride
Catalog No.:BCC1661
CAS No.:374559-48-5
[Immunosuppresive effects of wilfortrine and euonine].[Pubmed:2618700]
Yao Xue Xue Bao. 1989;24(8):568-72.
Wifortrine and Euonine isolated from Tripterygium wilfordii Hook. f. Wilfortrine and euonine (40.80 mg/(kg.d) x 4d ip) showed marked depressant effects on humoral mediated immunity using the hemolysin reaction as indices. Wilfortrine (160 mg/kg.d x 9d ip) exhibited a depressant effect on graft vs host reaction (GVHR), but Wilfortrine (80 mg/(kg.d) x 9d ip) showed no definite effect. Euonine (80 mg/(kg.d) x 10d ip) showed marked suppressant effects on DNCB induced delayed hypersensitivity reaction on skin in mice. Wilfortrine and Euonine (80 mg/(kg.d) x 4d ip) significantly decreased the clearance rate of charcoal particles and the weights of spleen and thymus.
Effect of Combined Treatment Using Wilfortrine and Paclitaxel in Liver Cancer and Related Mechanism.[Pubmed:27043783]
Med Sci Monit. 2016 Apr 4;22:1109-14.
BACKGROUND: Liver cancer is a common malignant tumor with high mortality. Currently, effective medicines against liver cancer are still lacking. Paclitaxel is a wide-spectrum anti-tumor agent, while Wilfortrine has been shown to have an inhibitory effect on the proliferation of liver cancer cells. This study thus investigated the potential effect of paclitaxel combined with Wilfortrine on cultured liver cancer cells and related mechanisms, in order to provide evidence for pathogenesis and treatment of liver cancer. MATERIAL/METHODS: Liver cancer cell line HpeG2 was divided into control, paclitaxel, Wilfortrine, and combined treatment groups. Cell proliferation was tested by MTT, while invasion was detected in Transwell chamber assay. Apoptotic protein Bcl-2 and Bax expression levels were further quantified using real-time PCR and Western blotting. RESULTS: Both of those 2 drugs can effectively inhibit cancer cell proliferation, depress invasion ability, increase Bcl-2 expression, and elevate Bax expression levels (p<0.05 in all cases). The combined therapy had better treatment efficacy compared to either of those drugs alone (p<0.05). CONCLUSIONS: The combined treatment using Wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug.
Effect of wilfortrine on human hepatic cancer HepG2 cell proliferation potential in vitro.[Pubmed:26634500]
Genet Mol Res. 2015 Nov 30;14(4):15349-55.
Liver cancers are characterized by high morbidity and mortality owing to few effective drugs for its treatment. Wilfortrine has several pharmacological effects, including an inhibitory effect on liver cancer cell proliferation. However, whether Wilfortrine can induce liver cancer cell apoptosis has not been elucidated. We investigated the role of Wilfortrine on liver cancer cell HepG2 apoptosis and analyzed its possible mechanisms to provide a theoretical basis for clinical analysis of liver cancer pathogenesis. The liver cancer cell line HepG2 was treated with 40 mM Wilfortrine for 48 h. Flow cytometry was applied to detect HepG2 cell apoptosis and cell cycle changes. Western blot was used to analyze Bcl-2 and Bax expression. The HepG2 cell apoptosis rate increased significantly after treatment with Wilfortrine, especially the early apoptosis rate (P < 0.05). However, Wilfortrine did not change the cell cycle of HepG2 cells. After Wilfortrine treatment, Bcl- 2 expression decreased significantly (P < 0.05); on the contrary, Bax expression increased noticeably compared with the control group (P < 0.05). Wilfortrine can induce liver cancer cell HepG2 apoptosis, but with no effect on the cell cycle, mainly by promoting Bax expression and inhibiting anti-apoptotic protein Bcl-2 expression.
